Vigeo Therapeutics Provides Update on VT1021 Treatment of GBM Expansion Patient
13 Jul 2023 //
PR NEWSWIRE
Vigeo will present Clinical & Immune Profiling Data from Ph I/II Expansion study
02 Jun 2023 //
PR NEWSWIRE
Vigeo New Immune Profiling and Biomarker Data Ph I/II Expansion study
25 May 2023 //
PR NEWSWIRE
GCAR, Biohaven, Vigeo Commence Biohaven’s Troriluzole and Vigeo’S VT1021 Trial
06 Jul 2022 //
BUSINESSWIRE
Vigeo Therapeutics Announces New Phase 1/2 Data from VT1021 Study
16 Nov 2021 //
BIOSPACE
Vigeo Announces New Phase 1/2 Data from its Expansion Study of VT1021
09 Nov 2021 //
PRNEWSWIRE

Market Place
Sourcing Support